Epcoritamab (Epkinly)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses epcoritamab (Epkinly) 4 mg in 0.8 mL (5 mg/mL), concentrate for solution for subcutaneous injection 48 mg in 0.8 mL (60 mg/mL), concentrate for solution for subcutaneous injection. Indication: Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL transformed from indolent lymphoma, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, or follicular lymphoma grade 3B after 2 or more lines of systemic therapy who have previously received, or are unable to receive, CAR T-cell therapy.